Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$-0.56
EPS est.
$-0.50
EPS surprise
-12.00%
1-day move
+10.39%
Twist Bioscience's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, rising by 10.39%. This increase may indicate that investors are looking past the EPS miss, possibly due to other factors not disclosed in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | $-0.18 | -12.00% |
| Revenue | — | $115M | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Twist Bioscience Corporation is a biotechnology company that specializes in DNA synthesis and gene editing. Operating in the health care sector, its innovative technology is crucial for advancements in medicine, agriculture, and industrial applications.
Last quarter
In Q2-2026, Twist Bioscience reported an EPS of $-0.71, which was worse than expected, leading to a significant drop in stock price the following day. The company continues to face challenges in meeting analyst expectations.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
+14.51%
Avg 1-day reaction
+0.19%
Analysts are cautiously optimistic about Twist's upcoming earnings, expecting a slight improvement in revenue but still projecting a loss per share. The market is closely watching for any signs of recovery.
Bull case
If Twist can exceed revenue expectations and show signs of narrowing losses, it could indicate a turnaround in business performance, boosting investor confidence.
Bear case
Conversely, if the company fails to meet revenue targets or reports wider losses, it could lead to further declines in stock price, reflecting ongoing operational challenges.
Key metrics to watch
EPS
$-0.18Earnings per share is a key indicator of profitability and financial health, and this quarter's consensus reflects ongoing challenges.
Revenue
$115MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Twist achieve revenue of at least $115M this quarter?
Meeting or exceeding this revenue target is crucial for demonstrating demand and operational stability, which could influence investor sentiment.
Q2
How does the company plan to address its ongoing losses?
Investors will be looking for concrete strategies or improvements that could lead to a path towards profitability, which is vital for long-term growth.
—
Est. EPS
$3.49
Est. Rev
$721M
Impl. Move
±12.5%
Why consensus could be wrong
The consensus may underestimate Twist's potential for revenue growth due to new product launches that have not yet been fully reflected in analyst models.
Supporting evidence
The company has been investing in expanding its product offerings, which could drive higher sales than anticipated.
Options pricing suggests a significant move, indicating that traders expect more volatility and possibly better performance than the consensus.
Past earnings surprises show that Twist has the ability to outperform expectations when conditions align.
Key risk
If revenue exceeds $115M, it could challenge the current negative sentiment and shift the narrative around the company's growth prospects.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal for determining whether the company can recover from recent disappointments and regain investor confidence.
Bull confirmed if
Revenue exceeding $115M with a narrower EPS loss than consensus would confirm a positive outlook.
Bear confirmed if
An EPS loss greater than $-0.18 alongside revenue below $115M would reinforce negative sentiment.
What the market is pricing for the move.
Implied Move
±39.3%
Historical Avg
±9.2%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.
Options are pricing ±39.3% while TWST has averaged ±9.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
71.2%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$21.0M
110,997 sh
6 insiders
Net
$21.0M
Net selling
Most Active Insiders· 25 open-market trades
$10.6M
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Twist beats expectations, history suggests a potential stock increase of around +0.91%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.
Miss
A miss could result in a decline of approximately -6.11%, reflecting continued concerns about the company's performance.
The lines on the call that would change the story.
$4.9M
Net selling
$1.9M
Net selling
$1.8M
Net selling
Recent Transactions
Oct 2, 2026 · @ $188.88
45,736 sh
$8.6M
Oct 2, 2026 · @ $188.88
25,714 sh
$4.9M
Oct 2, 2026 · @ $188.88
10,088 sh
$1.9M
Oct 2, 2026 · @ $188.88
9,514 sh
$1.8M
Oct 2, 2026 · @ $188.88
8,057 sh
$1.5M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.